drugset / Trial / NCT01712009

NOLAN: Naproxen or Loratadine and Neulasta

NCT01712009

Phase 2 Completed 600 enrolled Amgen
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic loratadine.

Timeline

Start
2012-11-01
Primary completion
2015-03-18
Completion
2015-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Loratadine Small molecule 10 mg
Subject Naproxen Small molecule 500 mg Oral
Background Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous

Indications